EGFR and non-small cell lung carcinoma: Having initially shown limited efficacy against NSCLC patients with classical EGFR mutations who had acquired the T790M resistance mutation [50], subsequent in silico modeling highlighted a potential activity for poziotinib to target the structure of EGFR exon 20 insertions [26].